Results 11 to 20 of about 180,906 (186)

Seasonal Mass Vaccination With R21/Matrix-M for Malaria Elimination (SERVAL): Protocol of the Cluster Randomised Trial [PDF]

open access: yesTrials
Introduction Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools.
Balla Gibba
exaly   +3 more sources

R21/Matrix-M Malaria Vaccine Drives Diverse Immune Responses in Pre-Exposed Adults: Insights From a Phase IIb Controlled Human Malaria Infection Trial [PDF]

open access: yesFrontiers in Immunology
IntroductionThe recently licenced R21/Matrix-M vaccine induces a protective antibody response. In this study, we examined vaccine-induced responses in semi-immune adults in a controlled human malaria infection (CHMI) Phase IIb clinical trial ...
Lisa Stockdale   +2 more
exaly   +4 more sources

The role of R21 expression in differential diagnosis of melanocytic lesions

open access: yesIndian Journal of Pathology and Microbiology, 2023
Background: Cyclic adenosine monophosphate (cAMP) is an intracellular signal transmitter involved in the regulation of melanocyte growth, proliferation, and melanogenesis.
Didem Turcan   +2 more
doaj   +2 more sources

Psychological correlates of eating behavior in overweight/obese adolescents in Taiwan: Psychometric and correlation analysis of the Three-Factor Eating Questionnaire (TFEQ)-R21

open access: yesPediatrics and Neonatology, 2021
Background: The Three-Factor Eating Questionnaire (TFEQ) is a self-assessment scale used widely in the studies of eating behavior, but its short form TFEQ-R21 has not been validated in the Taiwanese population.
Yu-Wen Lin   +6 more
doaj   +2 more sources

Preclinical Evaluation of the SMNP-Adjuvanted R21 Malaria Vaccine Across Multiple Mouse Strains [PDF]

open access: yesVaccines
Background: Adjuvants can enhance the immunogenicity of virus-like particle (VLP) vaccines. VLP-based malaria vaccines (RTS,S and R21) have demonstrated the potential of this approach and have now been deployed in many countries. However, the efficacy of
Gulbuse Turan   +3 more
doaj   +2 more sources

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context [PDF]

open access: yesBMJ Global Health
Background The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. The vaccine will soon be deployed at scale in sub-Saharan Africa.
Jayne Webster   +13 more
doaj   +2 more sources

Efficacy and safety of RTS, S and R21 malaria vaccines in children under five in Africa: a systematic review and meta-analysis of randomized controlled trials [PDF]

open access: yesMalaria Journal
Background Malaria remains a major public health burden in Africa, particularly among children under five years of age. By consolidating findings across randomized controlled trials on the RTS,S and R21 malaria vaccines, this study seeks to provide an ...
Khulud Mahmood Nurani   +9 more
doaj   +2 more sources

Readiness of R21 Malaria Vaccine Introduction in Tertiary Hospitals in Northern Nigeria [PDF]

open access: yesIbom Medical Journal
Context: The R21 malaria vaccine was introduced in Nigeria to augment the already existing malaria control and prevention strategies. However, there is scepticism regarding its implementation success, especially in the Northern region. Aim: The study
Haruna JJ   +8 more
doaj   +2 more sources

N,N-Dimethylanilinium 2,4,6-trinitrophenolate

open access: yesActa Crystallographica Section E, 2009
In the title compound, C8H12N+·C6H2N3O7−, there are N—H...O and C—H...O interactions which generate R21(5), R21(6) and R12(6) ring motifs.
Nagarajan Vembu, Frank R. Fronczek
doaj   +2 more sources

Awareness, Acceptability, and Willingness to Pay for the R21/Matrix-M Malaria Vaccine: A Cross-Sectional Study Among Pregnant Women and Nursing Mothers in Enugu State, Nigeria

open access: yesBMC Public Health
Background The R21/Matrix-M vaccine has significantly reduced incident malaria in children aged 3–36 months, but awareness, acceptance, and affordability of the vaccine are key to its successful rollout.
Abdulmuminu Isah   +1 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy